nsc 664704 has been researched along with Glioblastoma in 1 studies
kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitabayashi, T | 1 |
| Dong, Y | 1 |
| Furuta, T | 1 |
| Sabit, H | 1 |
| Jiapaer, S | 1 |
| Zhang, J | 1 |
| Zhang, G | 1 |
| Hayashi, Y | 1 |
| Kobayashi, M | 1 |
| Domoto, T | 1 |
| Minamoto, T | 1 |
| Hirao, A | 1 |
| Nakada, M | 1 |
1 other study available for nsc 664704 and Glioblastoma
| Article | Year |
|---|---|
Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Topics: Animals; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dru | 2019 |